Literature DB >> 34406849

Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?

Paolo Tarantino1,2, Sara M Tolaney3,4, Nadia Harbeck5, Javier Cortes6,7, Giuseppe Curigliano1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34406849     DOI： 10.1200/JCO.21.01059

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Impact of the COVID-19 Pandemic on Breast Cancer Management in Portugal: A Cross-Sectional Survey-Based Study of Medical Oncologists.

Authors:  Diogo Alpuim Costa; José Guilherme Gonçalves Nobre; João Paulo Fernandes; Marta Vaz Batista; Ana Simas; Carolina Sales; Helena Gouveia; Leonor Abreu Ribeiro; Andreia Coelho; Margarida Brito; Mariana Inácio; André Cruz; Mónica Mariano; Joana Savva-Bordalo; Ricardo Fernandes; André Oliveira; Andreia Chaves; Mário Fontes-Sousa; Mafalda Sampaio-Alves; Diogo Martins-Branco; Noémia Afonso
Journal:  Oncol Ther       Date:  2022-03-21

Review 2.  Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer.

Authors:  Francesco Schettini; Mario Giuliano; Matteo Lambertini; Rupert Bartsch; David James Pinato; Concetta Elisa Onesti; Nadia Harbeck; Diana Lüftner; Sylvie Rottey; Peter A van Dam; Khalil Zaman; Giorgio Mustacchi; Joseph Gligorov; Ahmad Awada; Mario Campone; Hans Wildiers; Alessandra Gennari; Vivianne C G Tjan-Heijnen; Javier Cortes; Mariavittoria Locci; Ida Paris; Lucia Del Mastro; Sabino De Placido; Miguel Martín; Guy Jerusalem; Sergio Venturini; Giuseppe Curigliano; Daniele Generali
Journal:  Cancers (Basel)       Date:  2021-09-01       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.